You are here:

MS in the media - 26 August 2016

Published on

20-26 August 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Genes and vitamin D

Australian research that will be presented at a conference this week has found a connection between two genes associated with MS risk and levels of vitamin D.  The research has not looked to see if increasing vitamin D makes the genes act correctly

Source: Sydney Morning Herald

MS Trust link: Vitamin D

Siponimod trial in secondary progressive MS

Results of a trial of siponimod found people on treatment took longer to show signs of progression than people on placebo. Disability (EDSS scores) was measured every three months. Other results, including progression measured with EDSS every six months, have not yet been released

Source: Novartis press release
Source: NMSS

MS Trust link: Siponimod (BAF312)

Amiselimod trial results

A phase II study in people with relapsing remitting MS has found that higher doses of amiselimod reduced the number of new lesions seen on MRI compared to both placebo and a lower dose of the drug

Source: Medical News Bulletin

MS Trust link: Drugs in development